Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Barthold Deiters"'
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 346-352 (2024)
Abstract Pharmacotherapy options for chronic lymphocytic leukaemia (CLL) have expanded significantly in recent years. These options include chemotherapy, chemoimmunotherapy and signalling pathway inhibitors. A notable shift in the treatment landscape
Externí odkaz:
https://doaj.org/article/a272d399f5184520b66231f0ded0566f
Autor:
Miguel Á. Canales Albendea, Pier Luigi Canonico, Guillaume Cartron, Barthold Deiters, Claudio Jommi, Reinhard Marks, Catherine Rioufol, Juan M. Sancho Cia, Armando Santoro, Eva M. Wagner-Drouet
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionCAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient’s immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In the European Union (EU
Externí odkaz:
https://doaj.org/article/c8df2e3381f24b3992a5551e93803778
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background For stroke prevention in patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists (VKA). For some patients a lower dosage of DOACs (ld-DOACs) is
Externí odkaz:
https://doaj.org/article/d098868f40614891bef3273e36cb06a2
Publikováno v:
BMJ Open, Vol 13, Iss 1 (2023)
Objectives Direct oral anticoagulants (DOACs) were introduced based on randomised controlled trials (RCTs) comparing them to vitamin-K-antagonist (VKA) warfarin. In Germany, almost exclusively phenprocoumon is used as VKA. RCTs with phenprocoumon bei
Externí odkaz:
https://doaj.org/article/2dfbf57c48f44740973054708f861e73
Autor:
Evi Zhuleku, Beatriz Antolin-Fontes, Andras Borsi, Riikka Nissinen, Ivana Bravatà, Jennifer Norma Barthelmes, Manuela Le Bars, Jennifer Lee, Alun Passey, Ulf Maywald, Barthold Deiters, Bernd Bokemeyer, Thomas Wilke, Marco Ghiani
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: The positioning of new biologic agents for the treatment of Crohn’s disease (CD) following failure of initial anti-tumor necrosis factor (anti-TNF) therapy remains a challenge in the real world. Objectives: This study aims to investigat
Externí odkaz:
https://doaj.org/article/4921b8a95db043c59dfae7f2e19ab1de
Publikováno v:
BMJ open. 13(1)
ObjectivesDirect oral anticoagulants (DOACs) were introduced based on randomised controlled trials (RCTs) comparing them to vitamin-K-antagonist (VKA) warfarin. In Germany, almost exclusively phenprocoumon is used as VKA. RCTs with phenprocoumon bein
Publikováno v:
Abstracts.
Autor:
Thomas Wilke, Nils Picker, Sabrina Müller, Anna Stürmlinger, Barthold Deiters, Axel Dittmar, Jens Aberle, Maximilian Gabler
Publikováno v:
ClinicoEconomics and Outcomes Research.
Thomas Wilke,1 Nils Picker,2 Sabrina Müller,2 Anna Stürmlinger,3 Barthold Deiters,4 Axel Dittmar,1 Jens Aberle,5 Maximilian Gabler3 1IPAM e.V., Wismar, Germany; 2Ingress-Health HWM GmbH, Wismar, Germany; 3Boehringer Ingelheim Pharma GmbH & Co.K
Autor:
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Publikováno v:
Journal of Clinical Oncology. 41:464-464
464 Background: This study assessed real-world treatment (tx) and outcomes in patients with metastatic urothelial carcinoma (mUC) in Germany. Methods: Using 2 statutory health insurance (SHI) claims databases (SHI 1 and SHI 2; 2013-2020, ≈8 million
Autor:
Antje Mevius, Alina Brandes, Fränce Hardtstock, Thomas Wilke, Boris A. Ratsch, Hans-Dieter Orzechowski, Andreas Fuchs, Barthold Deiters, Bernd Bokemeyer
Publikováno v:
Digestion. 102:216-226
Objectives: This study aimed to assess the real-world rates of treatment discontinuation and switching of biologic therapies in patients with inflammatory bowel disease (IBD). Methods: A retrospective claims data analysis on all continuously insured